The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Novel agents showing promise for the treatment of double-refractory CLL
Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses emerging classes of agents being explored for relapsed chronic lymphocytic leukemia (CLL), highlighting the focus on patients who are double-refractory. Dr Thompson notes that non-covalent BTK inhibitors, BTK degraders, and bispecific antibodies are being developed, with some agents showing promise in early-phase trials. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
